Medication Guide for Talatumumab_Conhule

Talatuzumab is an innovative bispecific antibody drug specifically used to treat extensive-stage small cell lung cancer (ES-SCLC). The drug activates T cells by targeting DLL3 and CD3, providing a new treatment option for patients who are ineffective with traditional treatments. This article will introduce in detail the usage and dosage of talatumumab, precautions during the medication course, and possible side effects, to help medical staff and patients better understand this treatment plan.

Talatuzumab usage and dosage

’s usage and dosage are designed to balance efficacy and safety, with special attention to reducing the risk of adverse reactions such as cytokine release syndrome (CRS).

Administration and dosage regimen

Talatuzumab is administered by intravenous infusion, with each infusion lasting 1 hour. It is recommended to adopt a stepwise escalation dose regimen: 1 mg is given on the first day of cycle 1, increased to 10 mg on the 8th day, and then 10 mg is given every two weeks for maintenance treatment. This incremental approach can effectively reduce the incidence and severity of CRS.

Pretreatment and monitoring requirements

On days 1 and 8 of Cycle 1, 8 mg of dexamethasone (or equivalent dose) must be administered intravenously within 1 hour before infusion. Immediately after the infusion, 1 liter of normal saline was infused intravenously for 4-5 hours. Patients need to be closely observed for 22-24 hours at a medical institution equipped with CRS monitoring conditions, and should remain near the medical institution within 48 hours after infusion.

Drug Preparation Method

For 1 mg specification, add 1.3 mL of sterile water for injection for reconstitution, and for 10 mg specification, add 4.4 mL. Dilution must be completed within 4 hours after reconstitution, and infusion bags and catheters made of EVA, polyolefin or PVC should be used.

Strictly following these medication specifications can significantly improve the safety and effectiveness of treatment.

Talatumumab treatment course

Talatumumab treatment requires a reasonable treatment plan based on the patient's individual conditions and adjustments at any time.

Treatment cycle schedule

After completing the initial dose escalation, administration will be given every two weeks until disease progression or unacceptable toxicity occurs. Assess complete blood count and liver function before each dose.

Dose adjustment strategy

Treatment needs to be suspended when neutrophils <1.0×10^9/L or platelets <50×10^9/L occur. Depending on the severity of the adverse reaction, dose reduction or dosing interval extension may be necessary.

Restart plan after treatment interruption

If treatment interruption is ≤14 days (1mg dose) or ≤21 days (10mg dose), the original plan can be directly resumed; beyond this time limit, the dose needs to be increased from 1mg again.

Individualized treatment management is an important factor in ensuring long-term treatment success.

Side effects of talatumumab

Understanding the potential side effects of talatumumab can help to identify and deal with adverse reactions in a timely manner.

Cytokine release syndrome (CRS)

CRS is the most common adverse reaction, manifesting as fever, hypotension, fatigue, etc. Level 1-2 can be treated symptomatically, while level 3-4 requires suspension of treatment and ICU support.

Nervous system toxicity

Neurotoxic symptoms such as confusion and drowsiness may occur. Severe cases require dexamethasone treatment and suspension of administration if necessary.

Hematological abnormalities

Hematological toxicities such as neutropenia and anemia are common. Routine blood tests need to be monitored regularly, and febrile neutropenia requires immediate treatment.

Patients should promptly identify and properly handle these side effects during medication.